Phenoxypropazine

Phenoxypropazine

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	℞ (Prescription only)
Identifiers
IUPAC name (1-methyl-2-phenoxy-ethyl)hydrazine
CAS Number	3818-37-9
PubChem (CID)	71467
ChemSpider	64548
UNII	8E92V52324
ChEMBL	CHEMBL1909286
Chemical and physical data
Formula	C9H14N2O
Molar mass	166.22 g/mol

Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.^{[1][2][3][4][5]}

See also

• Hydrazine (antidepressant)

References

1. LEAHY MR, ROSE JT, PLOWMAN R (April 1963). "A preliminary study of phenoxypropazine in the treatment of depression". The American Journal of Psychiatry. 119: 986–7. PMID 13928824.
2. IMLAH NW (May 1963). "Preliminary report on phenoxypropazine". The American Journal of Psychiatry. 119: 1091–2. PMID 13956423.
3. ROSE JT, LEAHY MR, PLOWMAN R (October 1963). "A comparison of phenoxypropazine and amitriptyline in depression". The American Journal of Psychiatry. 120: 393–5. PMID 14069469.
4. ROSE JT (March 1964). "Phenoxypropazine and chlordiazepoxide in depression". The American Journal of Psychiatry. 120: 899–900. PMID 14129290.
5. MCWHINNEY IR, MORRELL DC (January 1965). "Treatment of mild endogenous depression with a monoamine oxidase inhibitor: a controlled trial in general practice". The Journal of the College of General Practitioners. 9: 95–9. PMC 1878242. PMID 14254271.